» Articles » PMID: 25823656

Loss of β-catenin in Adrenocortical Cancer Cells Causes Growth Inhibition and Reversal of Epithelial-to-mesenchymal Transition

Overview
Journal Oncotarget
Specialty Oncology
Date 2015 Apr 1
PMID 25823656
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

Adrenal carcinoma (ACC) is a rare neoplasm with a poor outcome. Aberrant expression of β-catenin has been found in approximatively 30% of ACC. We herein studied its effects on the growth of the human ACC cell line H295R. The cells were infected with short hairpin RNA (shRNA)-mediated silencing β-catenin. Two shRNAs used induced down-regulation of β-catenin protein levels. The expression of these shRNAs decreased cell growth and increased H295R cells in S and G2/M phases. This cytostatic effect is due to a decrease of phosphorylated MAPK and to an up-regulation expression of the cyclin-dependent kinase inhibitors p57(KIP2), p21(CIP) and p27(KIP1). In addition, the knockdown of β-catenin decreased phosphorylated Akt and increased apoptosis. Finally, loss of β-catenin was sufficient to induce the reversal of the epithelial-to-mesenchymal transition. We then transplanted these genetically modified H295R cells in Scid mice. Tumor growth suppression was achieved by the two shRNAs showing in vitro efficacy. Proliferation was not reduced in silenced tumors. In contrast, p57, p27 and p21 proteins were found expressed at high levels in silenced tumors along with an increase in apoptotic cells. These findings indicate that β-catenin loss in H295R cells inhibits tumor growth by inducing transcriptional and functional changes.

Citing Articles

A reappraisal of transcriptional regulation by NR5A1 and beta-catenin in adrenocortical carcinoma.

Lalli E Front Endocrinol (Lausanne). 2023; 14:1303332.

PMID: 38155952 PMC: 10753177. DOI: 10.3389/fendo.2023.1303332.


Preclinical assessment of synergistic efficacy of MELK and CDK inhibitors in adrenocortical cancer.

Laha D, Grant R, Mishra P, Boufraqech M, Shen M, Zhang Y J Exp Clin Cancer Res. 2022; 41(1):282.

PMID: 36151566 PMC: 9502945. DOI: 10.1186/s13046-022-02464-5.


Cellular Senescence in Adrenocortical Biology and Its Disorders.

Gao X, Li F, Liu B, Wang Y, Wang Y, Zhou H Cells. 2021; 10(12).

PMID: 34943980 PMC: 8699888. DOI: 10.3390/cells10123474.


Inhibition of Aurora kinase A activity enhances the antitumor response of beta-catenin blockade in human adrenocortical cancer cells.

Maria A, Borges K, Lira R, Hassib Thome C, Berthon A, Drougat L Mol Cell Endocrinol. 2021; 528:111243.

PMID: 33716050 PMC: 8297658. DOI: 10.1016/j.mce.2021.111243.


A novel heat shock protein 90 inhibitor potently targets adrenocortical carcinoma tumor suppression.

Wang T, Subramanian C, Blagg B, Cohen M Surgery. 2019; 167(1):233-240.

PMID: 31561992 PMC: 8513613. DOI: 10.1016/j.surg.2019.06.052.


References
1.
Verma U, Surabhi R, Schmaltieg A, Becerra C, Gaynor R . Small interfering RNAs directed against beta-catenin inhibit the in vitro and in vivo growth of colon cancer cells. Clin Cancer Res. 2003; 9(4):1291-300. View

2.
Heaton J, Wood M, Kim A, Lima L, Barlaskar F, Almeida M . Progression to adrenocortical tumorigenesis in mice and humans through insulin-like growth factor 2 and β-catenin. Am J Pathol. 2012; 181(3):1017-33. PMC: 3432433. DOI: 10.1016/j.ajpath.2012.05.026. View

3.
Giles R, van Es J, Clevers H . Caught up in a Wnt storm: Wnt signaling in cancer. Biochim Biophys Acta. 2003; 1653(1):1-24. DOI: 10.1016/s0304-419x(03)00005-2. View

4.
Jho E, Zhang T, Domon C, Joo C, Freund J, Costantini F . Wnt/beta-catenin/Tcf signaling induces the transcription of Axin2, a negative regulator of the signaling pathway. Mol Cell Biol. 2002; 22(4):1172-83. PMC: 134648. DOI: 10.1128/MCB.22.4.1172-1183.2002. View

5.
Vaishnaw A, Gollob J, Gamba-Vitalo C, Hutabarat R, Sah D, Meyers R . A status report on RNAi therapeutics. Silence. 2010; 1(1):14. PMC: 2908561. DOI: 10.1186/1758-907X-1-14. View